$XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity Nasdaq:XOMA

XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological ActivityBERKELEY, Calif., June 8, 2011 GLOBE NEWSWIRE — XOMA Ltd. Nasdaq:XOMA, a leader in the discovery and development of therapeutic antibodies, released six-month top line results from a Phase 2a clinical trial of XOMA 052 in 74 patients with Type 2 diabetes. The results were as expected based on data from the Phase 2a three-month interim review and the Phase 2b trial. XOMA 052 was well tolerated with no significant differences between the XOMA 052 and placebo groups in observations of adverse events. XOMA 052 continued to show evidence of biological activity as shown by a reduction in levels of C-reactive protein, a biomarker of cardiovascular risk. There were no differences in glycemic control between the drug groups and placebo as measured by hemoglobin A1c levels. This Phase 2a trial was designed as an exploratory trial focused on overall safety and kinetics and was not designed to show statistically significant differences in measures of biological activity.

via XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity Nasdaq:XOMA.